WAVRE, Belgium — 21 June 2023: iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announces that it will be hosting a symposium where it will present three-year interim data from the STAR-GLOBAL trial and will also be running a dry lab at its booth at the 10th World Glaucoma Congress (WGC) taking place in Rome, Italy from 28 June-1 July 2023.
The symposium, ‘From Evidence-Based Data to Clinical Practice: Safety and Efficacy of Supraciliary MIGS,’ will take place on Thursday 29 June from 18:00-19:00 CEST in Room C and will be chaired by Steve R. Sarkisian, Jr., MD (Oklahoma Eye Surgeons, Oklahoma, US), with Dr Karsten Klabe (Breyer, Kaymak & Klabe Augenchirurgie, Düsseldorf, Germany) and Faisal Ahmed (Head of Specialty for Imperial College NHS Trust Ophthalmology Department, London, UK) as accompanying speakers. The symposium will also feature the presentation of new three-year interim data from the STAR-GLOBAL trial, which will be presented by Dr Inder Paul Singh, glaucoma specialist and President of The Eye Centres of Racine & Kenosha, Wisconsin, US.
In addition to the symposium at WGC, clinical data for MINIject®, the only commercially available supraciliary MIGS device, will be shared in the following presentations, posters and a poster walk:
Delegates are also invited to attend an Expert MINIject® Dry Lab at the iSTAR Medical booth (#D74), where surgeons can get hands-on experience with MINIject®. Register for the dry lab here: https://www.istar-medical.com/dry-lab-registration/
About iSTAR Medical
iSTAR Medical is committed to delivering breakthrough eye care solutions. Our most advanced product, MINIject®, is approved in Europe for the treatment of open-angle glaucoma – the leading cause of irreversible blindness – and we are aiming to seek market approval in the US. We believe MINIject®’s distinctive tissue-integrating capabilities unlock a safer, and more effective option for patients. We are building an exceptional team and pipeline of potentially leading products such as MINIject® to establish new treatment paradigms in eye care conditions with the highest patient needs.
iSTAR Medical is an independent company which entered a strategic partnership with AbbVie (NYSE: ABBV) in July 2022. The collaboration further supports the role of MINIject® in the treatment of glaucoma and accelerates iSTAR Medical’s goal to bring MINIject® to more patients globally while providing AbbVie the opportunity to further expand its diverse eye care portfolio.
MINIject® is iSTAR Medical’s innovative MIGS device for patients with primary open-angle glaucoma. MINIject® combines the distinctive porous structure of its proprietary STAR material with the power offered by the supraciliary space. As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications.
Glaucoma is a progressive disease affecting over 100 million people globally, of which primary open-angle glaucoma is the most common form.[1,2] IOP reduction, through medication or surgery, helps delay disease progression. Medication is generally the first line treatment, but the progressive addition of multiple drops can burden patients with side effects, compliance challenges and costs.[2,3] Invasive surgery can present risks with irreversible complications and often requires long-term patient management.[2,3] MIGS is the most promising and fastest-growing glaucoma therapy due to its enhanced safety profile. MINIject® is potentially best-in-class for its promising long-term efficacy and safety.
 Jonas JB, Aung T, Bourne RR et al. “Glaucoma”. Lancet 2017; 390: 2083–93
 Market Scope, “2021 Glaucoma Surgical Device Market Report”, July 2021. https://www.market-scope.com/pages/reports/267/2021-glaucoma-surgical-device-market-report
 “European Glaucoma Society Terminology and Guidelines for Glaucoma”, 4th Edition: British Journal of Ophthalmology. 2017;101:1-195 https://bjo.bmj.com/content/101/5/73